-
US Fed raises rates to tackle 'too high' inflation, irking Trump
-
US stocks fall, dollar gains after Fed lifts interest rates
-
Turkey releases 106 protesters, jails more LGBTQ activists
-
US Fed raises rates to tackle 'too high' inflation in move sure to rile Trump
-
Candidate for UN chief calls for AI regulation akin to nuclear weapons
-
US Fed raises rates to battle inflation in move likely to rile Trump
-
'We're losing control,' AI pioneer Yoshua Bengio tells AFP
-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
Global fuel price demos: a round-up
-
Toogood Gold's Table Mountain Sits in the Shadow of a Nevada Gold Rush
-
Leverate Launches MCP for Traders to Connect AI Assistants With Trading Platforms
-
MEXC July–August Security Report: 38.66M USDT in Risk Funds Intercepted, Futures Insurance Fund Hits 792M USDT
-
MEXC Launches $1M "Discover Your Wall Street DNA" Campaign to Help Traders Find Their Market Fit
-
Emporio Armani names Dario Vitale new creative director
-
Stocks edge higher ahead of US Fed rate call
-
EU to ban social media for under 13s, curb access until 15
-
BASIS.pro Expands On-Chain Infrastructure with XDC Network Partnership and Zypher DAO as Auto Earn Goes Live
-
Wildfires push endangered Sumatran elephants to brink: Indonesian NGO
-
Pickle-flavoured tart? AI inspires Japan's convenience stores
-
Bank of Japan set to raise rates under pressure from inflation, US
-
EU chief hosts Canada's Carney in push to 'deepen' alliance
-
EU chief to unveil social media, gaming curbs for under-15s
-
Meta chief pushes back on AI slowdown calls
-
'Resident Evil' film brings video game's ethos to the big screen
-
US Fed to deliver rate decision with markets betting on hike
-
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops
-
i-payout Expands U.S. Money Transmitter Licensing Footprint and Advances European EMI Strategy
-
Sanders, Bannon warn of AI dangers in rare US left-right alignment
-
US Senate crypto bill collapses amid partisan deadlock
-
Empty benches as schools reopen in Venezuela's quake-hit Guaira
-
OpenAI, Anthropic and Google are working to create an AI standards body
-
Tiny English village holds 'independence' vote over asylum seeker housing
-
Protesting shepherds, farmers clash with Romanian police
-
US Treasury chief says to meet Chinese counterpart at weekend
-
Foundation Lets Ledger Users Switch to Open Source Without Starting Over
-
BingX Evolves into a Multi-Asset Trading Platform, Connecting Users to Global Opportunities
-
EU to propose curbing social media, online games for under 15s
-
International Trading Institute Expands Professional Trader Development Beyond the Master’s in Trading
-
FX Junction Reaches 40,600 Members and 26 Million Trades
-
Lake Energy Secures $80 Million for U.S. Renewable Energy Expansion
-
'We unleashed the beast': the world's fears and hopes about AI
-
Stocks drop, oil climbs and Treasury yields hit 19-year high
-
Hospitality leaders ask Burnham to halve VAT amid rising costs
-
SkySail Strategies Outperforms Wall Street's 30-Year Risk Standard With Proprietary AI Inference Model
-
Worcestershire invited to nominate groups for 2027 King’s volunteer award
-
Just add fish: Scientists pursue more rice, less disease in Senegal paddies
-
Berlin's run-down public spaces at heart of election campaign
Appetite-regulating hormones in focus as first Nobel Prizes fall
Research into hormones that regulate appetite is seen leading the race for the Nobel Prize in Medicine, to be awarded Monday -- the first in this year's Nobel season.
At a time when more than one billion people suffer from obesity, research into the hormone called "glucagon-like peptide 1" (GLP-1) could be given the nod for the Nobel Prize in Physiology or Medicine this year, experts said.
A new generation of drugs using GLP-1 agonists -- including blockbuster brands Ozempic, Wegovy and Mounjaro -- has provided a valuable tool to fight obesity and diabetes globally.
"Many are guessing that it (the Nobel Prize in Medicine) will go to the people behind GLP-1," Lars Brostrom, science editor at public broadcaster Sveriges Radio, told AFP.
That could help researchers from major US institutions once again dominate the Nobel Prizes in sciences, which are to be announced this week in Stockholm.
But, even if that happens, US politics is to cast a shadow over them, given budget cuts to science programmes ordered by President Donald Trump's government.
Since January, the US National Institutes of Health (NIH) has terminated 2,100 research grants totalling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch.
Such cuts could fuel debate over the growing risk that the United States could lose its edge in scientific research.
"In the post-war period, the US has taken over Germany's role as the world's leading scientific nation," Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel Prizes in physics, chemistry, and economics, told AFP.
"When they now start cutting research funding, it threatens the country's position."
- Many contenders -
When it comes to GLP-1, as with many other discoveries, it can be hard to narrow down who exactly deserves to be honoured when many scientists around the world have made significant contributions.
Brostrom said some names often speculated upon are Danish physician Jens Juul Holst, and Joel Habener, a professor of medicine at Harvard, as well as Canadian endocrinologist Daniel Drucker and Yugoslav-born American chemist Svetlana Mojsov.
Despite treatments such as Ozempic being recently introduced, and the Nobel Assembly at the Karolinska Institute more often honouring discoveries that are decades old, "it could also be perfect timing" for GLP-1 recognition "because the discovery itself was made back in the 80s", Brostrom said.
In the same field, research on ghrelin, a hormone that stimulates appetite, could earn a Nobel Prize for two Japanese researchers, Kenji Kangawa and Masayasu Kojima, according to David Pendlebury, who heads research analysis at the firm Clarivate -- which predicts potential Nobel winners based on the number of citations of their work.
Pendlebury said that would also form "a nice bookend to a 1994 discovery" by geneticist Jeffrey Friedman, who discovered another appetite-regulating hormone, leptin, and who has previously been spotlighted by Clarivate.
"We have a combination of very nice discoveries, a hormone for appetite, a hormone that suppresses appetite, and this may also play into a lot of speculation of a prize for the GLP-1," he told AFP.
Clarivate also said the work of German medical professor Andrea Ablasser, American virologist Glen N. Barber, and Chinese-American biochemist Zhijian "James" Chen could be honoured "for elucidating the cGAS-STING pathway, a fundamental mechanism of innate immunity".
It noted that Canadian biologist John E. Dick could also be a contender "for identifying leukaemia stem cells and establishing their relevance in therapy failure".
- 'Invisibility cloak' -
For the Nobel Prize in Physics on Tuesday, experts at Sweden's public radio cited research into metamaterials, which has been buzzed about for several years.
British physicist John B. Pendry has in particular been frequently mentioned for his "invisibility cloak" -- a theoretical method to redirect electromagnetic fields around an object.
The Nobel season continues Wednesday with the prize for chemistry, followed on Thursday by the closely watched literature prize and on Friday the peace prize, which Donald Trump has argued should go to him.
The economics prize wraps up the Nobel season on October 13.
In addition to each honour, the prize includes a diploma, a gold medal, and a check for 11 million Swedish kronor ($1.2 million).
D.Avraham--CPN